PapersFlow Research Brief
Chronic Kidney Disease and Diabetes
Research Guide
What is Chronic Kidney Disease and Diabetes?
Chronic Kidney Disease and Diabetes refers to the intersection of chronic kidney disease (CKD), particularly diabetic nephropathy, with type 2 diabetes, encompassing estimation of glomerular filtration rate, albuminuria, renal insufficiency, cardiovascular risks, and management strategies including TGF-β signaling and fibrosis.
This field includes 51,972 papers on CKD aspects such as glomerular filtration rate estimation, diabetic nephropathy, and associations with cardiovascular disease. Key works develop equations like the MDRD Study equation for accurate GFR prediction from serum creatinine. Reduced estimated GFR shows graded risks for death, cardiovascular events, and hospitalization in community populations.
Topic Hierarchy
Research Sub-Topics
Estimated Glomerular Filtration Rate
This sub-topic develops and validates creatinine- and cystatin C-based eGFR equations across populations. Researchers address bias in MDRD, CKD-EPI, and race-free formulations.
Diabetic Nephropathy Pathophysiology
This sub-topic investigates hyperglycemia-induced glomerular hyperfiltration and mesangial expansion. Researchers study advanced glycation end-products and podocyte injury mechanisms.
CKD and Cardiovascular Disease
This sub-topic examines uremic cardiomyopathy, vascular calcification, and sudden cardiac death risk. Researchers analyze mineral bone disorder contributions to CV mortality.
Albuminuria and CKD Progression
This sub-topic studies albuminuric CKD phenotypes and renoprotective therapies. Researchers validate UACR thresholds predicting ESRD across diabetes and hypertension.
Global Burden of CKD
This sub-topic uses GBD methodology tracking CKD prevalence, DALYs, and attribution to diabetes/hypertension. Researchers forecast healthcare burdens under aging demographics.
Why It Matters
Chronic kidney disease linked to diabetes drives substantial clinical and public health challenges, as reduced estimated GFR independently associates with higher risks of death, cardiovascular events, and hospitalization in large community-based studies (Go et al. (2004) in "Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization"). Losartan treatment in patients with type 2 diabetes and nephropathy reduced end-stage renal disease risk by 25% and proteinuria progression, demonstrating renal and cardiovascular protection (Brenner et al. (2001) in "Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy"). Accurate GFR estimation via equations like the 4-variable MDRD equation enables better diagnosis and monitoring, supporting management in nephrology and diabetes care across global burdens documented in systematic analyses.
Reading Guide
Where to Start
"A New Equation to Estimate Glomerular Filtration Rate" by Levey et al. (2009), as it builds on prior MDRD work to provide the foundational CKD-EPI equation for GFR estimation, central to diagnosing CKD in diabetes patients.
Key Papers Explained
Levey et al. (1999) in "A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation" established the MDRD equation, which Levey et al. (2006) refined in "Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate" and further advanced to the CKD-EPI in Levey et al. (2009) "A New Equation to Estimate Glomerular Filtration Rate". Go et al. (2004) in "Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization" linked reduced GFR to outcomes, while Brenner et al. (2001) in "Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy" showed treatment impacts. Bikbov et al. (2020) in "Global, regional, and national burden of chronic kidney disease, 1990–2017" contextualizes prevalence.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease by Stevens et al. (2024) updates evaluation and management protocols, reflecting ongoing refinements in GFR-based staging and diabetes-related interventions.
Papers at a Glance
Frequently Asked Questions
What is the MDRD Study equation for estimating GFR?
The MDRD Study equation estimates glomerular filtration rate from serum creatinine more accurately than measured creatinine clearance or other equations in patients with chronic kidney disease. Levey et al. (1999) developed it in "A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation" using data from the Modification of Diet in Renal Disease Study. It provides reliable GFR estimates below 90 mL/min per 1.73 m² when using standardized serum creatinine.
How does reduced GFR relate to cardiovascular risks?
Reduced estimated GFR shows an independent, graded association with risks of death, cardiovascular events, and hospitalization. Go et al. (2004) observed this in "Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization" across a large community-based population. These risks highlight the clinical importance of identifying chronic renal insufficiency early.
What renal benefits does losartan provide in diabetic nephropathy?
Losartan reduces the progression to end-stage renal disease and proteinuria in patients with type 2 diabetes and nephropathy. Brenner et al. (2001) reported these outcomes in "Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy". The treatment was generally well tolerated.
What improvements did the CKD-EPI equation bring to GFR estimation?
The CKD-EPI equation estimates GFR more accurately across a broader range than the MDRD equation. Levey et al. (2009) introduced it in "A New Equation to Estimate Glomerular Filtration Rate" developed by the National Institute of Diabetes and Digestive and Kidney Diseases. It enhances precision for clinical use in CKD diagnosis.
What is the global burden of CKD according to recent analyses?
The Global Burden of Disease Study 2017 systematically analyzed CKD prevalence, incidence, and mortality from 1990 to 2017 at global, regional, and national levels. Bikbov et al. (2020) detailed this in "Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017". Findings quantify diabetes-related contributions to CKD burden.
How was the MDRD equation standardized for serum creatinine?
Standardized serum creatinine values in the MDRD equation improve GFR estimation accuracy below 90 mL/min per 1.73 m². Levey et al. (2006) reexpressed it in "Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate". Clinical labs can now report more precise eGFR values.
Open Research Questions
- ? How can GFR estimation equations be further refined for diverse populations beyond those in the MDRD and CKD-EPI studies?
- ? What mechanisms link TGF-β signaling and fibrosis specifically in diabetic nephropathy progression?
- ? Which interventions beyond losartan best mitigate cardiovascular risks graded by reduced GFR in diabetes patients?
- ? How does the global burden of CKD attributable to diabetes vary by region, and what drives disparities?
- ? What role does albuminuria play in predicting renal outcomes independent of GFR in type 2 diabetes?
Recent Trends
Field contains 51,972 works with focus sustained on GFR estimation and diabetic nephropathy; Stevens et al. in "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease" provides the latest guidelines, building on prior KDIGO efforts like Khwaja (2012), amid no new preprints or news in the last 6-12 months.
2024Research Chronic Kidney Disease and Diabetes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chronic Kidney Disease and Diabetes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers